Working… Menu
Trial record 94 of 172 for:    "Heart Disease" | "Heparin"

RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00317343
Recruitment Status : Withdrawn
First Posted : April 24, 2006
Last Update Posted : May 7, 2012
Information provided by:

Brief Summary:
RIAPRE is a non-interventional registry to be settled in Italy with the purpose of collecting data on 600 cases of high risk elective percutaneous coronary intervention (PCI) patients treated with an anticoagulation regime different from unfractionated heparin in monotherapy. About thirty catheterization laboratories will co-operate in this activity. The long term outcome of patients will be taken into consideration. The availability of these data will allow for a better understanding of the therapeutic needs in this area.

Condition or disease Intervention/treatment
Coronary Disease Drug: Bivalirudin (thrombin specific anticoagulant)

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: RIAPRE - A Non-interventional Registry on the Anticoagulation Treatment in High Risk Elective Percutaneous Coronary Interventions
Study Start Date : March 2006
Estimated Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Intervention Details:
  • Drug: Bivalirudin (thrombin specific anticoagulant)
    Percutaneous Coronary Intervention

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria :

  • Medical condition or disease to be studied: age > 18 years.
  • Patients are candidates for a PCI with a planned anticoagulation regime other than unfractionated heparin in monotherapy. Taking into consideration the national and international guidelines for this area and the registered indications of the drugs currently used for this purpose it is predicted that the patients will probably receive one of the following:

    • unfractionated heparin as an intravenous (IV) bolus followed by IV bolus + infusion of a GPI (abciximab, tirofiban or eptifibatide); or
    • bivalirudin as an IV bolus followed by IV infusion, as per the pertinent Summary of Product Characteristics (SPCs).
  • Having provided an informed consent (to anonymous data treatment).
  • A planned anticoagulation regime means that any candidate patient should be identified on the basis of pre-procedural factors and requested to give his/her consent before the PCI is initiated. Patients receiving bail-out GPI for intraprocedural complications should NOT be considered for the inclusion. However, a pre-included patient could receive a bail-out GPI if deemed necessary.
  • The allocation of any individual patient to the category of "high risk" elective PCI will be made independently and autonomously by the caring physician. However, it is recommended to consider the suitability of patients on the basis of these indicative elements:

    • age > 75 years.
    • known diabetes mellitus (type I or type II).
    • known renal insufficiency, i.e. serum creatinine > 1.8 mg or glomerular filtration rate (GFR) > 60 ml/min (calculated with the Cockroft formula).
    • multivessel or complex procedure.
    • planned stent on a bifurcation.
    • planned stent > 6 cm long.
    • PCI on a degenerated venous bypass: in this particular case a distal protection device should always be used.
    • non ST elevation acute coronary syndrome with a PCI planned later than 72 hours after the diagnosis without clinical instability (= "cooled" non ST elevation acute coronary syndrome). This type of patient is considered to be essentially stable and his/her level of risk can be comparable to the risk of patients who are candidates for elective PCI with additional risk factors as listed above.

Exclusion Criteria:

  • There will be no specific exclusion criteria other than those listed in the Summary of Product Characteristics of every individual agent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00317343

Sponsors and Collaborators
Layout table for investigator information
Study Chair: Nycomed Clinical Project Management Headquarters

Layout table for additonal information
Responsible Party: Nycomed Identifier: NCT00317343     History of Changes
Other Study ID Numbers: BI-006-IT
First Posted: April 24, 2006    Key Record Dates
Last Update Posted: May 7, 2012
Last Verified: May 2012
Keywords provided by Nycomed:
Patients candidate to a PCI with a planned anticoagulation regime other than unfractionated heparin in monotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Coronary Disease
Myocardial Ischemia
Cardiovascular Diseases
Vascular Diseases
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action